SSKN · As filed with the SEC

STRATA Skin Sciences balance sheet, by quarter

The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025
Assets
Current assets:
Cash and cash equivalents	7,912	7,076	5,966	6,512
Restricted cash	0	0	0	1,334
Accounts receivable, net of allowance for credit losses of $551 and $433 at December 31, 2025 and 2024, respectively	4,121	3,504	4,022	5,007
Inventories	2,814	3,058	3,236	2,659
Prepaid expenses and other current assets	753	634	550	364
Total current assets	15,600	14,272	13,774	15,876
Property and equipment, net	8,964	9,557	8,604	9,462
Operating lease right-of-use assets	920	1,005	1,092	1,179
Intangible assets, net	3,377	4,223	4,363	4,856
Goodwill	1,429	1,429	2,658	2,658
Other assets	231	231	231	231
Total assets	30,521	30,717	30,722	34,262
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	15,349	1,875	—	—
Accounts payable	2,758	2,955	2,945	2,816
Accrued expenses and other current liabilities	6,155	6,210	7,401	8,779
Deferred revenues	2,248	2,551	2,372	2,204
Current portion of operating lease liabilities	231	266	303	331
Current portion of contingent consideration	0	1,176	983	1,009
Total current liabilities	26,741	15,033	14,004	15,139
Long-term debt, net	0	13,435	15,270	15,231
Deferred revenues and other liabilities	184	199	264	292
Operating lease liabilities, net of current portion	688	736	780	835
Contingent consideration, net of current portion	0	0	96	96
Total liabilities	27,613	29,403	30,414	31,593
Stockholders’ equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 5,888,199 and 4,171,161 shares issued and outstanding at December 31, 2025 and 2024, respectively	6	5	4	4
Additional paid-in capital	257,307	255,772	253,369	253,241
Accumulated deficit	(254,405)	(254,463)	(253,065)	(250,576)
Total stockholders’ equity	2,908	1,314	308	2,669
Total liabilities and stockholders’ equity	30,521	30,717	30,722	34,262

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.